Results 41 to 50 of about 19,540 (227)

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono, Bruce A.C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease

Frontiers in Immunology, 2021
ObjectiveTo evaluate the characteristics of patients with autoimmune disease with hypogammaglobulinemia following rituximab (RTX) and describe their long-term outcomes, including those who commenced immunoglobulin replacement therapy.MethodsPatients ...
Joanna Tieu, Joanna Tieu, Joanna Tieu, Rona M. Smith, Rona M. Smith, Seerapani Gopaluni, Seerapani Gopaluni, Dinakantha S. Kumararatne, Mark McClure, Mark McClure, Ania Manson, Sally Houghton, David R. W. Jayne, David R. W. Jayne   +13 more
doaj   +1 more source

Quality of life in children with primary antibody deficiency. [PDF]

, 2014
Primary antibody deficiency disorders (PADs) can have an excellent outlook if diagnosed early and treated appropriately, but require lifelong treatment with immunoglobulin replacement.
Allwood, Z, Cale, C, Davies, G, Duran-Persson, C, Gaspar, H, Gilmour, C, Jones, A, Malcolmson, C, Titman, P   +8 more
core   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

When protein losing enteropathy persists: A case series of viral and lymphatic‐associated etiologies

JPGN Reports, EarlyView.
Abstract Protein‐losing enteropathy (PLE) is a rare condition that is characterized by loss of plasma protein in the intestines leading to hypoproteinemia with subsequent peripheral edema and possibly anasarca. The pathophysiology of PLE varies depending on the etiology and involves either intestinal mucosal injury or lymphatic system alterations ...
Natalie Jennings, Antonia C. Rovira, Pamela Castillo Rocha, Janelle Torres, Claudia M. Salgado, Miguel Reyes‐Múgica, Richard N. Arboleda, Fatima S. Hussain   +7 more
wiley   +1 more source

Elephantiasis nostras verrucosa: an atypical presentation following intrapelvic lymphoma [PDF]

, 2019
Elephantiasis nostras verrucosa is a progressively debilitating and disfiguring disease commonly presenting with verrucous, cobblestone-like papules, nodules, or plaques with nonpitting edema in the lower extremities.
Dahle, Sara E, Hadian, Yasmin, Isseroff, R Rivkah, Link, Daniel   +3 more
core  

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

SPLENIC HOMOTRANSPLANTATION. [PDF]

, 1964
During the past 12 months, five clinical whole-organ splenic homotransplantations have been carried out with the objective of providing active immunologic tissue for the recipient patients.
FUDENBERG, H, MARCHIORO, TL, RIFKIND, D, ROWLANDS, DT, STARZL, TE, WADDELL, WR   +5 more
core  

Unbalanced Immune System: Immunodeficiencies and Autoimmunity [PDF]

, 2016
Increased risk of developing autoimmune manifestations has been identified in different primary immunodeficiencies (PIDs). In such conditions, autoimmunity and immune deficiency represent intertwined phenomena that reflect inadequate immune function ...
CAPALBO, DONATELLA, CIRILLO, EMILIA, D'ASSANTE, ROBERTA, De Cataldis, M, Di Giacomo, C, GALLO, VERA, Gaudino, G, GIARDINO, GIULIANA, Lorello, P, PALAMARO, LOREDANA, PIGNATA, CLAUDIO, PRENCIPE, MARIA ROSARIA, ROMANO, ROBERTA   +12 more
core   +2 more sources

Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐CD19 CAR‐T Cells

Cancer Science, EarlyView.
Under normal conditions, CXCL12 stimulation induces CXCR4 degradation. In contrast, CAR19‐T cells expressing the CXCR4 S338X variant maintain receptor stability and sustain ERK and AKT signaling, which supports T‐cell effector function, migration, and survival. Therefore, the enhanced anti‐leukemic activity is conferred by CXCR4 S338X expression in CAR‐
Yushu Mao, Xiaodan Wang, Chun‐Hui Jin, Zhifeng Wei, Qinghao Ding, Ke‐Ke Zhang, Bo‐Wen Dong, Kai‐Wen Zheng, Yufei Hou, Tao Zhang, Wen‐Jie Zhao, Zheng Hu, Yong‐Guang Yang   +12 more
wiley   +1 more source